INOVIQ (ASX:IIQ), formerly BARD1 Life Sciences Ltd (ASX:BD1), is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. INOVIQ has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

Latest Media Releases

BARD1 Life Sciences Changes its Name to INOVIQ

08/12/2021 08:58:00

Change of company name to INOVIQ Ltd New code ASX:IIQ from 9 December 2021 INOVIQ represents ‘intelligent innovation’ as the Company builds an innovative portfolio of diagnostic and…

Latest News